Profil
Geoffrey E.
Clark is currently the Chairman at Ischemix, Inc. He was formerly the Chief Medical Officer at Citius Pharmaceuticals, Inc.
Postes actifs de Geoffrey E. Clark
| Sociétés | Poste | Début |
|---|---|---|
Ischemix, Inc.
 Ischemix, Inc. Pharmaceuticals: MajorHealth Technology Ischemix, Inc. is a privately-held drug development company based in an undisclosed location. The American company focuses on developing its family of cytoprotective compounds for serious diseases and conditions, with the primary focus being the development of its lead compound, CMX-2043, for the treatment of TBI. Ischemix is working to advance cytoprotective therapies. The company was founded in 1999 by Victor Shashoua, and David DeWahl has been the CEO of the company since 2013. | Président | - |
Anciens postes connus de Geoffrey E. Clark
| Sociétés | Poste | Fin |
|---|---|---|
| CITIUS PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 12/09/2014 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CITIUS PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Ischemix, Inc.
Ischemix, Inc. Pharmaceuticals: MajorHealth Technology Ischemix, Inc. is a privately-held drug development company based in an undisclosed location. The American company focuses on developing its family of cytoprotective compounds for serious diseases and conditions, with the primary focus being the development of its lead compound, CMX-2043, for the treatment of TBI. Ischemix is working to advance cytoprotective therapies. The company was founded in 1999 by Victor Shashoua, and David DeWahl has been the CEO of the company since 2013. | Health Technology |
